Ozgene PTY LTD
Bentley, WA
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Other
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 5 Parker Pl, Bentley WA 6102, Australia
- Website
- ozgene.com
- Founded
- 1999
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $92,166 |
| FY2025 | $21,267 |
| FY2024 | $0 |
| FY2023 | $223,932 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $92,166 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Gempharmatech LLC | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Ingenious Targeting Laboratory Inc. | Holbrook, NY | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Taconic Biosciences, Inc. | Germantown, NY | 112990 All Other Animal Production |
| Cyagen Biomodels LLC | Santa Clara, CA | 325414 Biological Product (except Diagnostic) Manufacturing |
| The Jackson Laboratory | Bar Harbor, ME | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Ozgene PTY LTD, an Australian limited liability company headquartered in Bentley, Western Australia, supplies genetically modified mouse models, gene targeting vectors, and specialized breeding services to the National Institutes of Health as a prime contractor on a full-and-open (non-set-aside) basis. The company operates 100% on the prime side across 103 federal awards with no subcontractor footprint and no identified parent contract vehicles beyond two IDIQs.
Ozgene's customer base is severely concentrated in NIH's infectious-disease and cardiovascular research programs. The National Institute of Allergy and Infectious Diseases accounts for 53 of 103 awards (86% of award count) and $53.7 million of the $55.1 million combined potential value across the entire portfolio — a concentration that dominates both volume and dollars. Four other NIH institutes account for the remaining 14% of awards and negligible incremental dollars: the National Institute of Child Health and Human Development (14 awards, $298 thousand), the National Heart, Lung, and Blood Institute (8 awards, $283 thousand), the National Institute of Allergy and Infectious Diseases (8 awards, $226 thousand), and the National Institute of Diabetes and Digestive and Kidney Diseases (6 awards, $203 thousand). The source lists the vendor under a top-customer category label "NIAID DEA OA Acquisitions" carrying the bulk of the NIAID volume; the remaining NIH institutes represent scattered follow-on activity rather than sustained programs.
Ozgene's core capability is the creation and maintenance of transgenic humanized knock-in mouse models, particularly hemoglobin variants (HBB, HBBS, HBBE) and conditional genetic models for immunology and metabolic research. Representative work includes a $99,840 NHLBI purchase order (July 2023) for creation of HBB, HBBS, and HBBE knock-in mice; a $66,350 NIAID order (September 2023) for gene targeting vector services; a $67,480 NHLBI purchase order (April 2026) for mouse colony breeding of transgenic humanized hemoglobin knock-in models; and a $57,742 NIAID order (August 2023) for mouse backcrossing. All work is awarded as firm fixed-price purchase orders with no set-aside designations. Work is performed in Australia or at specified U.S. locations (Boston, Bethesda) depending on the award. The company sits on two IDIQs: an indefinite delivery contract (HHSN272200900005I) carrying 43 task orders worth $2.2 million in combined potential value, and a second IDIQ (272025727) with one task order.
Award activity has been episodic — two awards in 2021, five in 2022, three in 2023, and only two in 2025, with one award in 2026 — reflecting project-based demand from NIH rather than sustained annual procurement cadence. Only three awards reach ultimate completion in the next twenty-four months, carrying combined potential value of $113 thousand, indicating minimal recompete exposure near term. Category coding shows 70 awards under NAICS "All Other Animal Production" and 53 under PSC "Live Animals, Not Raised For Food," confirming the breeding and genetic-model focus; 17 awards fall under testing laboratory services and 6 under biotechnology R&D.
Quick answers
Is Ozgene PTY LTD registered in SAM.gov?
Yes. Ozgene PTY LTD's SAM.gov registration is active through December 16, 2026.
What is Ozgene PTY LTD's CAGE code?
Ozgene PTY LTD's CAGE code is ZBG11, and its Unique Entity ID (UEI) is M8PAJV4B5ZL4.
How much has Ozgene PTY LTD received in federal contracts?
Federal contracts obligated $21,267 to Ozgene PTY LTD in fiscal year 2025 and $337,365 in fiscal years 2023 through 2027.
How does Ozgene PTY LTD rank among federal contractors?
Ozgene PTY LTD ranked #50 in NAICS 11299, #59 in NAICS 1129 and #68 in PSC 8820 in FY2025.
What is Ozgene PTY LTD's most recent federal award?
Ozgene PTY LTD's most recent federal contract award is The national heart, lung, and blood institute (NHLBI) requires mouse colony breeding services to support ongoing… (75N98026P00186), from Office of Logisitics and Acquisition Operations (NIH), on April 1, 2026.
On GovTribe
See Ozgene PTY LTD's full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors